Characterization of cell lines used in the study
Cell line . | B-cell stage . | Expression profile . | FLT-1 . | KDR . | FLT-4 . | VEGF, pg/mL . |
|---|---|---|---|---|---|---|
| RS4;11 | B-cell precursor | CD10-CD19+CD20+ | + | - | + | 10.3 |
| BV173 | B-cell precursor | CD10+CD19+CD20+ | + | - | + | 2.4 |
| REH | Pre-B cell | CD10+CD19+CD20+ | + | - | - | 20.0 |
| 697 | Pre-B cell | CD10+CD19+CD20+ | + | - | - | 1.5 |
Cell line . | B-cell stage . | Expression profile . | FLT-1 . | KDR . | FLT-4 . | VEGF, pg/mL . |
|---|---|---|---|---|---|---|
| RS4;11 | B-cell precursor | CD10-CD19+CD20+ | + | - | + | 10.3 |
| BV173 | B-cell precursor | CD10+CD19+CD20+ | + | - | + | 2.4 |
| REH | Pre-B cell | CD10+CD19+CD20+ | + | - | - | 20.0 |
| 697 | Pre-B cell | CD10+CD19+CD20+ | + | - | - | 1.5 |
The different ALL cell lines used in this study correspond to distinct stages of B-cell differentiation. Of note, the cell lines that correspond to more “differentiated” B cells express higher levels of FLT-1. Also shown are the VEGF receptor expression profile of the 4 cell lines studied, and their human VEGF production in vitro. Note that the 4 cell lines express FLT-1 and none express KDR.